COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

UC San Diego Helps Expand Parkinson’s Progression Markers Initiative

Clinical study to identify biomarkers of Parkinson’s disease, sponsored by The Michael J. Fox Foundation, will recruit 4,000 participants by the end of 2023

December 06, 2021  |  

After a decade of pioneering research, the Parkinson’s Progression Markers Initiative (PPMI) by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will see a major expansion. Entering its most ambitious phase yet, the clinical study will grow its in-clinic recruitment from 1,400 to 4,000 participants by the end of 2023. This is the latest step in PPMI’s mission to maintain the most robust open-access Parkinson’s data set in the world.

University of California San Diego School of Medicine joined PPMI shortly after its launch in 2010, and is now one of nearly 50 clinical sites around the world participating in the expansion. The international effort seeks to identify biomarkers of Parkinson’s disease to promote development of better treatments, potential cures and perhaps even prevention of the disease.

PPMI logo

UC San Diego School of Medicine is now recruiting adults with and without Parkinson’s disease to participate in the Parkinson’s Progression Markers Initiative sponsored by The Michael J. Fox Foundation. Photo credit: The Michael J. Fox Foundation

“When the Foundation started in 2000, we set out to change the game on how Parkinson’s research gets done,” said founder and actor Michael J. Fox, who was diagnosed with the disease in 1991.

"Two decades later, I'm proud that we have continued to meet this challenge and have become more than just a research organization, but a space where patients bring their wisdom and energy. PPMI's expansion is about getting this done, curing Parkinson's, boiling down to a biomarker that we can identify early on and prevent the disease from ever impacting another family."

UC San Diego School of Medicine is now recruiting people recently diagnosed with Parkinson’s and people aged 60 and older who do not have the disease, but are living with certain risk factors, which include genetics, gender, head trauma and exposure to certain environmental toxins.

Participants will undergo tests including motor, neuropsychiatric and cognitive examinations; brain imaging with DaTscan and MRI; and blood, urine, cerebrospinal fluid and DNA sampling.

In addition to the 4,000 in-clinic study participants, PPMI is also recruiting up to 100,000 additional participants to contribute over the web. The Foundation has set up an online platform where anyone over the age of 18 with or without Parkinson’s can participate.

“PPMI is revolutionizing the field’s understanding of Parkinson’s biology,” said Douglas Galasko, MD, PPMI principal investigator, co-director of the Shiley-Marcos Alzheimer’s Disease Research Center and professor in the Department of Neurosciences at the UC San Diego School of Medicine. “We have already obtained incredibly rich information that no other study has been able to, but there is still much more to uncover.”

The latest iteration of the study will benefit from new research tools that were not around when it began, including advanced brain imaging techniques, new cognitive assessments and wearable digital devices for tracking motor movement.

The findings will not only inspire new biological targets for treating Parkinson’s disease, said Galasko, but also increase the efficiency of clinical trials.

“One of the biggest things we found in the initial studies was that Parkinson’s looks a little different in each person. This variability makes it difficult for clinical trials to assess whether a treatment is actually working. By developing more rigorous measures to track disease progression, we can help clinical trials use fewer participants and more quickly decide if a drug or therapy is going to work.”

Galasko also highlighted the importance of PPMI’s approach in studying early stages of Parkinson’s disease. He said the earlier physicians can intervene, the greater the chance they will be able to slow progression of the disease and extend the patient’s quality of life.

Variability in disease expression has inspired another aspect of UC San Diego School of Medicine’s recruitment plans.

“We're especially interested in having the people we recruit reflect the diversity of people who live in San Diego and Southern California,” said Galasko. “A lot of what we’ve learned about Parkinson’s so far comes from study populations that are not fully representative of all people who live with the disease. In this next phase of recruitment, we’re trying to better understand the disease in people from all backgrounds.”

UC San Diego is recruiting from the Southern California region, and works with participants to arrange transportation and lodging for in-clinic visits.

For more information about enrolling in PPMI, please contact site coordinator Shawnees Peacock at 877-525-PPMI or srpeacock@health.ucsd.edu, or visit the PPMI website.

About The Michael J. Fox Foundation for Parkinson’s Research (MJFF)
As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding $1.5 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; creates a robust open-access data set and biosample library to speed scientific breakthroughs and treatment with its landmark clinical study, PPMI; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at www.michaeljfox.org, Facebook, Twitter, or LinkedIn.


Care at UC San Diego Health

Parkinson and Other Movement Disorders



Media Contact

Nicole Mlynaryk, Bigelow Science Communication Fellow
858-249-0456
npmlynaryk@health.ucsd.edu

Nicole Mlynaryk
858-249-0456
npmlynaryk@health.ucsd.edu

Share This Article


Related News

12/8/2020
UC San Diego researchers used brain organoids to identify two drug candidates that counteract the genetic deficiencies that cause Rett syndrome, a rare form of autism spectrum disorder.
12/23/2019
Spontaneous mutations in male sperm are linked to development of autism spectrum disorder. Researchers have created a way to measure mutations and estimate risk of ASD in future children. If develope ...
11/14/2019
Researchers identified non-coding regions of the human genome that control the development and function of four brain cell types and mapped genetic risk variants for psychiatric diseases. They found t ...
7/23/2019
UC San Diego researchers have used the transcriptome — the sum of all messenger RNA (mRNA) molecules expressed from genes — to map protein-gene interactions involved in Alzheimer’s disease.



Follow Us